Crossmark

Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation

Crossref DOI link: https://doi.org/10.1186/s12959-017-0160-2

Published Online: 2018-02-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Henskens, Yvonne M. C.

Gulpen, Anouk J. W. https://orcid.org/0000-0003-3000-8778
van Oerle, René

Wetzels, Rick

Verhezen, Paul

Spronk, Henri

Schalla, Simon

Crijns, Harry J.

ten Cate, Hugo

ten Cate-Hoek, Arina
More Information

Article History

Received: 20 October 2017

Accepted: 29 December 2017

First Online: 1 February 2018

Ethics approval and consent to participate

: The Institutional Review Board of the MUMC approved this study (December 2011, project number 114069).

: Not applicable

: HTC is consultant at Stago. The other authors state that they have no conflicts of interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below